与「Biotech」相关的搜索结果

At midnight on February 6th, earlier this year, the doorbell to our apartment rang. The doorbell was followed by a pounding on the door. I answered the door and a security person in our building handed me his phone. It was my oldest daughter Eloise. She had found my 26-year-old daughter unconscious on the floor of her apartment and had called 911. The EMT team was already there, but they did not know what was wrong with Lucy or to which hospital they would take her. I threw on some clothes and jumped in an Uber heading east toward Brooklyn. (Lucy lived alone in Williamsburg.) On the way, I learned that they were taking her to Elmhurst, a City trauma hospital in Queens. I arrived about five minutes after the ambulance to join Eloise, Lucy’s mom, and a friend, and waited to learn what was wrong. After about 15 minutes, I asked a nurse where she was. I looked over his shoulder to his computer. Next to her name, it said “non-responsive.” I walked into the emergency room and wandered around looking for her until I found her unconscious on a gurney surrounded by several doctors and nurses. By about 2:30am with the results from a CAT scan, Lucy’s doctors had determined that she had a massive brain hemorrhage and would need an emergency hemicraniectomy to release the pressure on her brain and remove the blood from the hemorrhage. I called our wonderful friend and family doctor Eddie Fisher and explained what was going on. He woke up Josh Bederson, Chairman of Neurosurgery at Mount Sinai, to find out more about Zach Hickman, the neurosurgeon on call that night. Dr. Bederson said Hickman was an excellent surgeon, which was comforting as we had no choice. The surgery to save Lucy’s life began around 3:15am and finished around 5:30am. It was successful. The following day, I joined Lucy in an ambulance while she was being transferred to Mount Sinai on Madison Avenue. Later that day, we determined from Lucy’s Oura ring that her hemorrhage had occurred around 9am, which meant that more than 19 hours had passed from the time of the hemorrhage to the completion of the surgery to release the pressure on her brain (I only wish @ouraring had an alert for this kind of a medical event. Imagine it could call a family member if the wearer doesn’t cancel the alert). I later learned that the standard of care is not to do surgery to save a patient with a large brain bleed if more than five hours have passed since the hemorrhage. Even when the surgery is done, I was told that the likely outcome for the patient is a few months in a nursing home and death from pneumonia. When I met Lucy’s doctors, I did my best to inspire them: “Let’s see what can be accomplished if we give her the best care possible and we invest unlimited resources to restore her to life.” And I promised that whatever we learned we would make available to everyone. Dr. Chris Kellner, her neurosurgeon, and Dr. David Putrino, Director of Rehabilitation Innovation for the Mount Sinai Health System have led Lucy’s care team since that day. Words cannot describe the remarkable and compassionate care that she has received beginning with the EMT team and then from nurses, doctors, therapists, and the army of people who have worked to save her and return her to life. To this day, we have a daily Zoom where we discuss her progress and make adjustments to her care. While her care and oversight have been incredible, the learnings for the Mount Sinai team have also been elucidating and will assist in the care of many others. Lucy began in a bad place. She was in a coma for several weeks and then awoke not being able to breathe on her own, unable to walk, see or speak. Over the last six months, she has recovered her cognition – she understands everything including her circumstance – is able to walk a hundred or more steps at a time with assistance, is making progress with sounds, vowels and consonants and the beginnings of speech, but she remains unable to see. Each day, she makes a little progress, and daily progress compounds. Every day I tell her that she just needs to make a little progress and it won’t be long before she is back. We remain optimistic that Lucy will return to normal function. It will likely take years, but I believe it is only a matter of time, hard work, and technological progress, along with some, and perhaps a lot, of divine intervention. Many people have been praying for Lucy and we are incredibly grateful for the prayers and remarkable support she has received. Lucy’s friends have been with her every day since the beginning, and their presence and friendship have saved her life and helped to rebuild and maintain her spirit. And on a very positive note, Lucy’s challenge has brought together our entire modern family who have all been incredibly devoted to her care and recovery. Lucy's vision and other faculties may require some form of brain computer interface, work that is underway at Neuralink, Precision Neuroscience, Science, Synchron, Nudge, and other companies in the space. If you are going to have a devastating brain injury, now is the best time in history for that to happen. We are living in a world when you can be confident that the blind will soon see again. We are going to do everything we can to help make that happen, including by assisting existing companies in the space. With respect to our promise to make Lucy’s care available to others, we have made good progress. In May, a real estate colleague made me aware of a 93% vacant, brand new, 400,000 square foot Class A+ purpose-built biotech facility on West End Avenue between 65th and 66th Streets that missed the market and was available for sale. The Pershing Square Foundation acquired the building 60 days later. We also put under contract an adjoining 130,000 square foot building at 320 West 66th Street that is currently being used by Saturday Night Live for studio space. The building has 35-foot ceilings with massive column-free spaces that can be converted into superb rehabilitation facilities. We will close on the SNL building in December. We are also acquiring an adjoining vacant lot with additional air rights. With just the existing zoning rights, we can add a 150,000 square feet for a total of 680,000 square feet, a lab footprint larger than Rockefeller University, and that’s without including the potential for an upzoning that would allow for substantially more buildable area on the site’s 3.4 acres with spectacular views of the Hudson. Our goal is to build the world’s greatest brain research, rehabilitation, recovery, human optimization, and longevity institute. We have named it The Ackman Oxman Institute or the AOI for lack of a better name, but also to reinforce the point that Neri and I and our family are all-in on the mission. The AOI will be patient-centric. It will not be an academic research institute that produces lots of papers, a Nobel Prize winner or two, but little if any results for patients. We will be laser-focused on cures, treatments, devices, rehabilitation and exercise equipment, and targeted and basic research with a goal of massively accelerating the time from idea to innovation to production to helping a patient. While the AOI will be a non-profit, it will have highly commercial instincts. The AOI will have its own venture funding and will work to develop innovations to create companies that we will seed, assist, and spinout to ensure technologies, treatments, techniques, and drugs get to patients as promptly as possible. On one 3.4 acre campus in what is still the greatest city in the world, we will do neurosurgery, neuroscience, rehabilitation, nutrition, BCI and device development, human trials, hyperbaric oxygen treatments, and life extension programs, and we will mandate and incentivize collaboration among the teams with no silos, politics, bureaucracy, or any other constraint that is inconsistent with the mission. Mount Sinai will be an important partner and deservedly so, but it won’t be our only hospital or medical school partner as we don’t believe any institution has a monopoly on the best ideas or the best talent. We don’t believe in exclusive relationships because that is not in the best interest of patients. Five years ago, we considered launching a brain institute inspired by Neri’s mom who sadly died from Alzheimer’s. We couldn’t make the math work as the real estate was too expensive and we believed it would be too difficult to recruit the best talent from universities to our effort. Since then, the real estate became available at a 70% discount, universities became a much less attractive place to work due to politics outweighing meritocracy, protests that disrupt learning, the curse of antisemitism, and a decline in funding. Fortunately, during the same time, I made sufficient personal economic progress to make the AOI possible. The advance of AI in the last few years will also enable us to greatly accelerate our mission. AI still has a lot to learn about human intelligence and the brain, and the AOI should be at the forefront of the interplay between the brain and AI. Today, I am making a public filing disclosing a gift from Neri and me of ~$400 million or 10,000,000 shares of Pershing Square Inc. (PS) to the AOI. It is very early days for Pershing Square so these shares are intended to anchor the long-term work of the AOI as the shares compound over time while generating what we expect will be a growing stream of quarterly dividends to fund the Institute. We will also be announcing an additional gift of similar and potentially greater size which won’t be in the form of Pershing Square stock to provide the AOI with the short- and intermediate-term runway necessary to enable it to achieve its goal of becoming a self-sustaining institute, which reinvests all of its revenues, royalties, and the economic rewards of company formation to advance the fields of brain health and human longevity. Neri and I have chosen to anchor the funding of the AOI to maintain vision alignment and limit the need for the organization to focus on fundraising. We expect the AOI to be the best-resourced brain, rehab, recovery, and longevity institute in the world. We are grateful to have been able to form a board which includes Dean Kamen (our generation’s Thomas Edison), George Yancopoulus (CEO of Regeneron), James Rothman (Nobel Laureate), Bernardo Sabatini (neuroscientist), Chris Kellner (neurosurgeon), Olivia Flatto (CEO Pershing Square Foundation), Neri Oxman, and myself. We have recently identified a CEO who we expect to announce by October along with other key hires, and are beginning searches for a Chief Scientific Officer, a Chief AI/Technology Officer, a Chief Operating Officer, a Chief Financial Officer, and other key leadership roles. If you find what we are building compelling and want to be part of the leadership team that creates and builds the AOI from a standing start, please send an email to: search@aoiinst.org with a short note as to why you believe you can help. Please include your best three ideas for the AOI along with a summary of your background and your most important accomplishments. We promise strict confidentiality to those expressing interest in working with us. We have learned from Lucy that the brain can recover from even catastrophic injury. There is so much more work to be done as the mind is a terrible thing to waste. For details from my Pershing Square SEC filing see:

Precipio, Inc. (@PrecipioDx ) (@Nasdaq : $PRPO ) reported revenue of $7.0 million for the second quarter ended June 30, 2026, the highest quarterly revenue in the company’s history and an increase of 22% from $5.7 million in the second quarter of 2025. The specialty cancer diagnostics company validates its technologies clinically in its own laboratory before commercializing them for the global laboratory community. Precipio, Inc. is a B2i Digital (@b2idigital )Featured Company. See the company’s in-depth profile at: Both sides of the business contributed, with pathology services and diagnostic products each growing sequentially: • Revenue surpassed $7 million for the first time in company history, rising from $6.7 million in the first quarter • Product revenue reached $0.9 million, an increase of 21% over the previous high of $750,000 in the fourth quarter of 2025, and pathology revenue reached $6.1 million • Adjusted EBITDA, a non-GAAP measure the company reconciles in the release, was positive at $0.4 million for the quarter • Cash flow from operations was $0.7 million, and cash ended the quarter above $3 million against $1.1 million a year earlier • Management will discuss the quarter on a shareholder call on August 17, 2026 at 5 p.m. ET, followed by a moderated question and answer session The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Regarding the cash balance, Ilan Danieli, Chief Executive Officer of Precipio, stated: “We’ve achieved this level of cash without a financing event, demonstrating the strength of our operations. We’re encouraged by the progress we’ve made and believe we are well positioned to continue building on this momentum.” Read the full release: Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services that deliver higher accuracy, improved laboratory workflow, and better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in its laboratory where it designs, tests, validates, and uses these products clinically, then commercializes them as proprietary products that serve the global laboratory community. More information is available at Discover more emerging growth Featured Companies, Featured Experts, and upcoming Featured Conferences at B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at

There is immense potential for collaboration across diverse sectors such as digital technologies, artificial intelligence, cyber-security, fin-tech, digital public infrastructure, infrastructure development, renewable energy, advanced manufacturing, logistics, agriculture, food processing, pharmaceuticals, biotechnology and healthcare.

One thing I find striking in the discourse between AI 2040 and its detractors is that the two seem to be locked in to totally incompatible worldviews of how fast and how much of a big deal AI progress is: * In AI 2040, every scenario sees superintelligence of some kind emerging by 2040, unless a herculean effort is made to completely stop it * Detractors say things like "AI 2040 is naive about human coordination ability and a threat to freedom", but don't seem to see any naivety in assuming that the ASI transition will just go well by default, don't seem to see ASI itself as a massive power concentrator risk, and don't seem to feel fear of humanity's "hard power" dropping to zero if ASIs can do literally every task better than we can. This stance makes total sense in a "AI is normal technology" world, zero sense in a world where superintelligence is possible by 2030 and almost guaranteed by 2040 I think my beliefs are: - If I was confident that (present-day-style) AI is normal technology, I would be in the detractor camp - If I was confident that superintelligence is coming in 2030 by default, I would be closer to the AI 2040 camp - it's naive, but every other option is naive squared? But my problem is that I feel great uncertainty and have no idea which of the two worlds (or some other third thing) we're living in? Hence why I continue to be open-minded about slowdowns/pauses, but also I feel very uncomfortable with the "open source bad, the good outcome is the one where our guys have controlling global dominance" push coming from some major AI companies and intellectuals - in a "normal" world that's the sort of thing that triggers every political alarm bell at the same time. A big reason why I have been advocating and trying my best to support the d/acc platform (rapid up-skilling in formal verification, cryptography, secure and open hardware, pandemic resistance and other defensive biotech, food and basic resource security, public epistemics, non-power-concentrating versions of physical security) is that these things are clearly worth doing in both worlds. The 2040 plan is already much more open source friendly (even mandating it! yay). It also includes "mutually assured compute destruction" ideas which (if they work) effectively give one of 2-5 actors the ability to trigger a global compute winter - as opposed to giving 1-5 actors the ability to selectively disenfranchise people they consider baddies while exempting themselves. This is also a big improvement. So I can see the earnest attempts to improve along the dimensions detractors criticize on ("does this concentrate power in big AI labs and superpower governments?"), and I appreciate this. I think many people don't appreciate enough the differences between different "kinds" of pause buttons, and how some concentrate power far more than others. Probably we can think harder and improve even more here. But on the "slowdown/pause or not" topic, there isn't a magic "escape the tradeoff" button. The Hansonian in me says: the winning deal is a deal which, from the perspective of both sides' present-day beliefs and knowledge, both sides would accept, though for different reasons. If the crux is AI progress speed, then identify a set of pre-agreed triggers for "okay, serious shit is happening" [super-pandemics? >25% unemployment? something involving slaughterbots?], and pre-agree that we become much more open-minded to the slowdown or pause thing if enough triggers come to pass within some timeframe. 2040 detractors (who clearly implicitly think that we'll see amazing speedup of progress from AI but think that what I call the "serious shit" category is overhyped) will accept expecting that the triggers don't come to pass, and AI worriers will accept expecting that they will. Pre-agreeing on the specific triggers means that once the triggers either hit or don't hit, there is stronger legitimacy around the idea that one side's worldview turned out more correct and we should be more inclined toward their program. If I were @elonmusk (or zuck, or...) I would re-tool twitter much more heavily into being a platform for helping to identify and make these kinds of grand win-win deals, so that we can bypass big-country governments and big-company CEOs and big nonprofit intellectuals and give more people a voice in the discussion. It's possibly one of the best things that social media _could_ do for humanity if it wanted to. But again, maybe this is also naive. Actually, probably it's naive. But currently, I see zero plans for how to deal with an ASI transition that are not naive. Perhaps humanity is stuck with a choice between naive and naive squared (or maybe even naive squared and naive cubed), so I feel inclined to cut some slack to people who are trying.

This year, the EF is decreasing its budget by roughly 40%, which entails some difficult decisions. The goal of the decreases was set out in the Treasury Management Policy last year: the EF is transitioning into being a long-term-oriented endowment-based organization, shifting from its pre-2026 average of spending ~15% of its remaining funds each year, toward a post-2030 target of ~5% per year. Often, when an organization goes through something like this, people try to pretend that nothing of great value was lost, that it is an efficiency increase, that the only people cut are unproductive dead weight, and everyone else stopped partying, studied the blade, entered cracked S-tier beast mode, and this was sufficient to make up for the downside. I will not try to pretend this. I respect my EF colleagues far too much to pretend that there was not much that is lost. They are brilliant people. They are dedicated engineers of whom some have worked on the Ethereum protocol for nearly a decade. They have brought a bright light to the Ethereum ecosystem with their code, their words, their warmth as human beings and their actions. My dearest hope is that they find a path that brings them fulfillment and happiness whether inside Ethereum or outside. Hopefully many will be able to bring their excellent talents and mindset to the wider Ethereum ecosystem, or the even wider CROPS world. Instead, I will try to explain what *are* some of the grand sacrifices being made. The Ethereum Strawmap is no small thing. It is an extremely ambitious undertaking seeking to replace and augment almost every part of the protocol - consensus, proofs, privacy, account model, state, and more. This is the third iteration of Ethereum, in the same way that the Merge was the second, even if the shipping style is less Big Bang and more one-piece-at-a-time. On top of this, the EF is increasing its role in the Access Layer. We are not compromising on Ethereum being a Deeply Impressive protocol, something worthy of its place in a world with quantum computing, rockets to Mars and powerful biotech and AI, and capable of meeting the challenges that this era will bring. Some of the deficit will be recovered through more work happening outside the EF. But not all. So what are the grand sacrifices that will enable a leaner effort to accomplish all of this? I will give a few examples (though far from an exhaustive list): * The multi-client model will shift in the direction of multiple clients existing less for _redundancy_, and more for _specialization_. Up to this point, redundancy has been the main security strategy: if one client has a bug, if it has less than 33%, the chain keeps going and does not even stop finalizing. We are increasingly exploring moving more pieces of the protocol to a different security strategy: AI-assisted formal verification. Some smaller pieces of Ethereum (eg. BLS libraries) have worked this way already for a long time. But soon many more parts of Ethereum will likely function on this model. This may greatly reduce resource requirements of shipping a large number of EIPs. The resources saved by client teams can ideally instead be used to better serve different specialized user needs, including EF Access Layer goals. * PSE (Privacy and Scaling Explorations) is winding down as a unit. The number of people working on ZKPs for privacy and scaling is probably as high as ever, but they are working less on "exploration" and more on *implementing* ZKP-based privacy and scaling into the Protocol and Access Layer * Devcon will likely over time become smaller-scale, somewhat more spartan, much lower-deficit than previous years, in addition to other changes in vision in line with the Mandate. * Fewer beyond-Ethereum megaprojects coming from EF. As I announced earlier this year, I am taking on some of the responsibility of doing projects in this category that I consider valuable with my personal funds. * EF institutional work is reducing in scope, specializing more specifically on creating replicable test cases of highly CROPS-friendly deployments, even if at smaller scale. These do not explain all departures; in some cases they do not explain departures at all and rather explain _reduced need for new spending_. But they are a large part of the strategy at play. In the longer term, I personally favor a "soft lean-and-done" approach to Ethereum: once the Strawmap is completed, generally stick to security fixes and small high-value changes, and have a much higher bar for considering new feature additions to the protocol. This allows Ethereum to remain capture-resistant without demanding very large budgets. Learn less from multimillion-line-of-code behemoth projects, more from bitcoin. The past years have been a challenging era for Ethereum. However, the ecosystem is adapting, both inside the EF and outside, and I am confident that Ethereum is very well-positioned to succeed and thrive.

This year, the EF is decreasing its budget by roughly 40%, which entails some difficult decisions. The goal of the decreases was set out in the Treasury Management Policy last year: the EF is transitioning into being a long-term-oriented endowment-based organization, shifting from its pre-2026 average of spending ~15% of its remaining funds each year, toward a post-2030 target of ~5% per year. Often, when an organization goes through something like this, people try to pretend that nothing of great value was lost, that it is an efficiency increase, that the only people cut are unproductive dead weight, and everyone else stopped partying, studied the blade, entered cracked S-tier beast mode, and this was sufficient to make up for the downside. I will not try to pretend this. I respect my EF colleagues far too much to pretend that there was not much that is lost. They are brilliant people. They are dedicated engineers of whom some have worked on the Ethereum protocol for nearly a decade. They have brought a bright light to the Ethereum ecosystem with their code, their words, their warmth as human beings and their actions. My dearest hope is that they find a path that brings them fulfillment and happiness whether inside Ethereum or outside. Hopefully many will be able to bring their excellent talents and mindset to the wider Ethereum ecosystem, or the even wider CROPS world. Instead, I will try to explain what *are* some of the grand sacrifices being made. The Ethereum Strawmap is no small thing. It is an extremely ambitious undertaking seeking to replace and augment almost every part of the protocol - consensus, proofs, privacy, account model, state, and more. This is the third iteration of Ethereum, in the same way that the Merge was the second, even if the shipping style is less Big Bang and more one-piece-at-a-time. On top of this, the EF is increasing its role in the Access Layer. We are not compromising on Ethereum being a Deeply Impressive protocol, something worthy of its place in a world with quantum computing, rockets to Mars and powerful biotech and AI, and capable of meeting the challenges that this era will bring. Some of the deficit will be recovered through more work happening outside the EF. But not all. So what are the grand sacrifices that will enable a leaner effort to accomplish all of this? I will give a few examples (though far from an exhaustive list): * The multi-client model will shift in the direction of multiple clients existing less for _redundancy_, and more for _specialization_. Up to this point, redundancy has been the main security strategy: if one client has a bug, if it has less than 33%, the chain keeps going and does not even stop finalizing. We are increasingly exploring moving more pieces of the protocol to a different security strategy: AI-assisted formal verification. Some smaller pieces of Ethereum (eg. BLS libraries) have worked this way already for a long time. But soon many more parts of Ethereum will likely function on this model. This may greatly reduce resource requirements of shipping a large number of EIPs. The resources saved by client teams can ideally instead be used to better serve different specialized user needs, including EF Access Layer goals. * PSE (Privacy and Scaling Explorations) is winding down as a unit, and its underlying task (working on ZKP and related tech to support privacy and scaling) is shifting from an "exploration" strategy to a "build specific things we know are important" strategy, which requires less resources. * Devcon will likely over time become smaller-scale, somewhat more spartan, much lower-deficit than previous years, in addition to other changes in vision in line with the Mandate. * Fewer beyond-Ethereum megaprojects coming from EF. As I announced earlier this year, I am taking on some of the responsibility of doing projects in this category that I consider valuable with my personal funds. * EF institutional work is reducing in scope, specializing more specifically on creating replicable test cases of highly CROPS-friendly deployments, even if at smaller scale. These do not explain all departures; in some cases they do not explain departures at all and rather explain _reduced need for new spending_. But they are a large part of the strategy at play. In the longer term, I personally favor a "soft lean-and-done" approach to Ethereum: once the Strawmap is completed, generally stick to security fixes and small high-value changes, and have a much higher bar for considering new feature additions to the protocol. This allows Ethereum to remain capture-resistant without demanding very large budgets. Learn less from multimillion-line-of-code behemoth projects, more from bitcoin. The past years have been a challenging era for Ethereum. However, the ecosystem is adapting, both inside the EF and outside, and I am confident that Ethereum is very well-positioned to succeed and thrive.

卧槽兄弟们！！ 华尔街又要被我们收割了？？？ 散户在美股做微盘，就像毫无保护裸冲高杠杆合约——满眼20倍贪婪，却看不见头顶悬着的清算热力图！！市值不到10亿的修罗场里，看PE和财报纯自欺欺人。 真正能20倍爆炸的，本质就是一张没有到期日的虚值期权！暴涨从来不靠业绩线性增长，而是三大底层逻辑共振：流动性枯竭后的Gamma逼空 + 算力/能源物理资产化映射 + 纯二元事件驱动（FDA/军工订单）。 还在用传统估值选股？兄弟你就是流动性提款机！！白嫖党福音：当前资金暗流最猛的10个高弹性标的，按顶级游资分类逻辑降维拆解。 别手动了，直接抄作业冲！一、算力与能源的“物理化 RWA”映射 AI的尽头是电力，这些微盘电力/矿企就是活生生的算力RWA资产。 英伟达期权链固化后，热钱必然往下找高杠杆替代品。 CIFR 卧槽！曾经比特币挖矿纯打野，现在全面转HPC+AI数据中心！核心不是矿机，是电网底下签的那些廉价长期购电协议。 数据中心电荒一爆发，这玩意儿就是最硬的通缩资产！ IREN 兄弟们，市值小到离谱，对AI算力敏感度却极高！自带高倍杠杆的现货属性，一旦降息放水，资金冲基础设施，它戴维斯双击会直接起飞！ OKLO 纯SMR微型核反应堆叙事龙头！零营收，靠“AI需要核电”+OpenAI创始人光环硬撑。别用基本面看，只能用资金费率和持仓量去交易！核电+AI，这波叙事直接拉满！ 二、流动性黑洞与Gamma逼空阵区 常年被机构重度做空，盘口极轻。不需要基本面变好，只需让空头“觉得痛”。做市商对冲Delta狂买正股时，烟花直接绽放！SOUN 卧槽，边缘AI语音概念！空头头寸巨大，还时不时有英伟达持股利好。走势就是一张清算热力图，跌穿支撑洗盘后，一点火星就能连环爆仓，拉升速度快到离谱！ BBAI Palantir影子股，主打军工防务AI。极低流通盘+高度集中筹码，期权玩家最爱战场。随便拿个中型国防部订单，Gamma Squeeze直接引爆！ NNOX AI医疗影像赛道，长期在“颠覆医疗”和“可能破产”之间横跳。做空比例极高，一旦冷阴极X射线技术大规模商业化验证，空头踩踏血腥程度将史诗级！ 三、绝对的二元期权：零或无限 胜率可能不到20%，但盈亏比爆炸。要么政府批文/临床数据一飞冲天，要么原地归零。就是配置极小仓位的彩票库。 LUNR 月球物流运输，被美国国家机器绑定的航天微盘股。每次NASA合同竞标就是一次生死轮盘赌！只适合事件真空期潜伏，靴子落地别追高！ ACHR eVTOL龙头之一。催化剂超级明确——FAA最终适航认证！纯纯的监管二元博弈！ QBTS 量子退火计算先驱，盘子极小。量子计算还在炼金术阶段，不需要盈利，只要一个“突破量子霸权”PR稿，市值就能重估10倍！ SAVA 阿尔茨海默症药物研发，Biotech最臭名昭著也最血脉贲张的标的。数据造假争议+奇迹疗法交织，三期临床盲盒一开，不是天堂就是地狱！ 兄弟们，这10张暗牌就是顶级游资的降维打击逻辑！传统估值在微盘修罗场就是死路一条，抓住Gamma逼空、RWA映射、二元事件三大共振，才能真正收割华尔街！ 白嫖党们福音已到，别手动了，你怎么看呢？